We found that a high level of GASC1 was closely associated with worse response to NCT and poor survival of ESCC patients, which could provide a theoretical basis for the development of a new therapeutic strategy of ESCC. The gene discussed is KDM4C; the disease is esophageal squamous cell carcinoma.